查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1933910

肿瘤浸润淋巴细胞疗法市场按适应症、细胞来源、生产模式、最终用户和分销管道划分，全球预测（2026-2032年）

Tumor-Infiltrating Lymphocyte Therapy Market by Indication, Cell Source, Manufacturing Model, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，肿瘤浸润淋巴细胞疗法市场价值将达到 4.8079 亿美元，到 2026 年将成长至 5.5292 亿美元，到 2032 年将达到 16.0085 亿美元，复合年增长率为 18.74%。

主要市场统计数据
基准年 2025 4.8079亿美元
预计年份：2026年 5.5292亿美元
预测年份：2032年 16.85亿美元
复合年增长率 (%) 18.74%

我们将对肿瘤浸润淋巴细胞疗法进行严格的临床和操作概述，包括迄今为止的进展、当前挑战和转化研究重点。

肿瘤浸润淋巴细胞（TIL）疗法是一种基于细胞的免疫疗法，它利用患者自身的免疫细胞来识别和清除癌细胞。该技术包括分离自然浸润肿瘤组织的淋巴细胞，在体外扩增这些细胞以维持其功能，然后在进行预处理以增强移植效果后，将其回输给患者。过去十年，TIL疗法已从学术概念验证研究发展到多中心临床试验，并在某些固态肿瘤中展现出持久的疗效，这重新激发了临床研究人员和生物製药公司对该疗法的兴趣。

了解更多关于技术创新、临床组合、监管调整和商业策略的加速融合如何重塑治疗格局的资讯。

由于技术、临床和商业性因素的共同作用，肿瘤浸润淋巴细胞（TIL）疗法领域正经历着变革性的转变。细胞分离技术和培养系统的进步降低了生产过程中的变异性，缩短了扩增时间，从而实现了更一致的产品特性，并促进了多中心试验的进行。同时，基因组学和蛋白​​质组学分析的改进提高了识别肿瘤反应性克隆的能力，从而优化了患者选择标准，并提高了特定亚组患者获得持久疗效的可能性。

分析2025年美国关税对供应链、生产决策和临床时间表的多面向营运和策略影响

2025年实施的关税和贸易政策变化对包括TIL计画在内的先进细胞疗法的研发和应用产生了复杂的后续影响。关键试剂、一次性反应器、低温运输包装和专用一次性设备的供应链通常跨越多个地区，而进口关税的增加会推高这些投入品的成本，并造成采购瓶颈。因此，由于采购限制导致生产流程延误和临床试验入组时间延长，申办方面临着更为迫切的时间表。

提供以细分市场主导的整合观点，将临床适应症、细胞来源选择、终端用户环境、分销管道和生产​​模式与策略联繫起来。

深入了解肿瘤浸润淋巴细胞（TIL）的细分对于优化TIL疗法的临床、生产和商业策略至关重要。在适应症方面，研究主要集中在乳癌、肺癌和黑色素瘤，每种肿瘤都表现出独特的肿瘤微环境、免疫浸润模式以及先前对免疫疗法的反应。这些差异影响着检测设计、生物标记开发和终点选择。例如，由于黑色素瘤具有免疫抗原性，因此一直是TIL疗法的早期试验对象，而乳癌和肺癌计画通常需要更精细的选择标准和联合治疗来克服免疫环境的异质性。

检验关键地区的法规结构、临床基础设施和支付方环境如何影响药物的采纳和存取策略。

区域趋势将在塑造TIL疗法的临床开发重点、监管策略和准入模式方面发挥关键作用。在美洲，主要癌症中心的集中、成熟的细胞疗法生产网络以及活跃的投资者群体，为早期临床应用和试点商业项目创造了有利条件。该地区的法规结构日益强调在快速审批管道和严格品质要求之间取得平衡，鼓励申办方在寻求加速审批机制的同时，提供可靠的安全性和持久性数据。

整合创新者、製造商、诊断提供者和合作伙伴的策略行动，从而塑造竞争差异化和规模效应。

TIL疗法领域的企业策略融合了研发密集型创新企业、专业製造商、诊断开发商和策略合作伙伴。创新企业注重差异化的细胞分选方法、效力检测法以及针对特定适应症和联合治疗的临床项目；而生产型企业则透过自动化扩增系统和封闭式一次性平台，在实现规模化生产方面发挥着关键作用。诊断生物标记公司致力于精准筛选患者并进行长期监测，从而建立检查室能力与临床结果之间的重要桥樑。

建议经营团队采取具体的营运、临床和商业措施，以扩大治疗服务范围并降低商业化过程的风险。

业界领导者应采取务实且多管齐下的方法，在管理营运和财务风险的同时，加速TIL疗法的开发和应用。首先，应优先投资于自动化闭环生产系统，以降低生产变异性并提高产量。这些投资对于从客製化製程过渡到可重复的商业化生产至关重要。其次，透过多元化供应链并对关键试剂和一次性耗材的冗余供应商进行认证，保护营运免受地缘政治和关税相关因素的影响。

本文描述了一种严谨的混合调查方法框架，该框架整合了专家访谈、监管和临床证据、营运案例研究以及供应链图谱。

本分析采用质性和量性调查方法结合的研究途径，以确保研究结果的可靠三角验证。主要研究包括对肿瘤领域的关键产业领袖、细胞治疗生产总监、医院药房主任和临床实验室研究人员进行结构化访谈，以收集有关营运限制、临床设计重点和实施驱动因素的第一手观点。此外，也对同侪审查文献、监管指导文件和临床试验註册资讯进行了系统性回顾，以了解TIL计画的临床和安全性背景。

最后，我们简要总结了扩大病患就医途径和维持长期影响所需的科学潜力、操作要务和协作行动。

肿瘤浸润淋巴细胞疗法正处于关键的转折点，科学的成熟度与生产、监管和报销等方面的实际需求交汇融合。该疗法在某些固态肿瘤中诱导持久疗效的潜力，使其成为现有免疫疗法的重要补充，前提是研发人员能够克服物流和实证方面的挑战。细胞分选方法、封闭式生产系统和联合治疗的进步，为更广泛地应用该疗法提供了清晰的路径。然而，要充分发挥其潜力，需要整个生态系的协同投资。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章 美国关税的累积影响，2025年

第七章 人工智慧的累积影响，2025年

第八章：依适应症分類的肿瘤浸润淋巴球疗法市场

  • 乳癌
  • 肺癌
  • 黑色素瘤

9. 依细胞来源分類的肿瘤浸润淋巴球疗法市场

  • 同种异体移植
  • 自体

第十章 依生产模式分類的肿瘤浸润淋巴球疗法市场

  • 契约製造
  • 内部生产

第十一章 肿瘤浸润淋巴细胞疗法市场（按最终用户划分）

  • 医院
  • 研究所
  • 专科诊所

第十二章 肿瘤浸润淋巴球疗法市场（依通路划分）

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 肿瘤浸润淋巴球疗法市场（依地区分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 肿瘤浸润淋巴球疗法市场（依组别）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国肿瘤浸润淋巴球疗法市场概况

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国肿瘤浸润淋巴球疗法市场

第十七章：中国肿瘤浸润淋巴球治疗市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Achilles Therapeutics
  • Adaptimmune Therapeutics plc
  • Anocca AB
  • Atreca Inc.
  • Cellectis SA
  • Celularity Inc.
  • GammaDelta Therapeutics Ltd.
  • Immatics NV
  • Instil Bio Inc.
  • Iovance BIoTherapeutics Inc.
  • Kite Pharma Inc
  • Lyell Immunopharma Inc.
  • Nykode Therapeutics ASA
  • Obsidian Therapeutics Inc.
  • PACT Pharma Inc.
  • Poseida Therapeutics Inc.
  • Precigen Inc.
  • RheinCell Therapeutics GmbH
  • SQZ BIoTechnologies Company
  • Tessa Therapeutics Ltd.
  • TILT BIoTherapeutics
  • TScan Therapeutics Inc.
  • Turnstone Biologics Corp.
Product Code: MRR-C36616F699BD

The Tumor-Infiltrating Lymphocyte Therapy Market was valued at USD 480.79 million in 2025 and is projected to grow to USD 552.92 million in 2026, with a CAGR of 18.74%, reaching USD 1,600.85 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 480.79 million
Estimated Year [2026] USD 552.92 million
Forecast Year [2032] USD 1,600.85 million
CAGR (%) 18.74%

Introduce a precise clinical and operational overview of tumor-infiltrating lymphocyte therapy that frames historical progress, current challenges, and translational priorities

Tumor-infiltrating lymphocyte (TIL) therapy represents a cell-based immunotherapeutic approach that harnesses the patient's own immune cells to recognize and eradicate tumor cells. The technique isolates lymphocytes that have naturally migrated into tumor tissue, expands them ex vivo under conditions that preserve functionality, and re-infuses them into the patient following a preparative regimen intended to enhance engraftment. Over the past decade, TIL therapy has advanced from academic proof-of-concept studies to multicenter clinical investigations, demonstrating durable responses in select solid tumors and prompting renewed interest from clinical investigators and biopharma sponsors.

Importantly, TIL therapy occupies a distinct niche within the immuno-oncology landscape because it leverages tumor-reactive repertoires already present in patients rather than relying solely on engineered receptors. Consequently, translational research has focused on optimizing cell selection, reducing time-to-product, improving persistence post-infusion, and managing toxicities associated with lymphodepletion and cytokine support. Furthermore, regulatory agencies have signaled openness to expedited pathways for therapies addressing high-unmet-need oncology indications, which has catalyzed development activity. As clinical experience accumulates, stakeholders increasingly prioritize standardization of manufacturing, reproducible potency assays, and integration of companion diagnostics to identify patients most likely to benefit.

Looking ahead, TIL therapy's trajectory will depend on coordinated advances in patient selection, manufacturing scalability, and evidence generation that aligns clinical endpoints with payer expectations. While challenges remain-especially in operationalizing complex cell therapies within hospital settings and aligning stakeholders across clinical and commercial functions-the therapeutic modality offers a compelling route to deepen durable responses in solid tumors that historically responded poorly to other modalities. Consequently, strategic planning must address both near-term clinical adoption hurdles and longer-term infrastructure investments to support broader patient access.

Detail the accelerating convergence of technological advances, clinical combinations, regulatory adaptations, and commercial strategies reshaping the therapy landscape

The TIL therapy landscape is undergoing transformative shifts driven by converging technological, clinical, and commercial forces. Advances in cell isolation technologies and culture systems have reduced manufacturing variability and shortened expansion timelines, enabling more consistent product profiles and facilitating multicenter trials. Concurrently, improvements in genomic and proteomic profiling have sharpened the ability to identify tumor-reactive clones and to refine patient selection criteria, thereby increasing the probability of durable responses in targeted subpopulations.

At the clinical level, combination strategies pairing TIL therapy with checkpoint inhibitors, targeted agents, or modulators of the tumor microenvironment are generating signals that reframe therapeutic sequencing and trial design. These combination approaches aim to potentiate TIL efficacy by mitigating local immunosuppression and enhancing intratumoral trafficking. From a commercial standpoint, the growing interest in both autologous and investigational allogeneic paradigms is prompting investment in modular manufacturing platforms, point-of-care capabilities, and partnerships between clinical centers and specialized contract developers.

Regulatory dynamics have also shifted, with agencies emphasizing quality-by-design, potency-based release criteria, and adaptive clinical pathways that accommodate accelerated evidence generation. Meanwhile, payers are increasingly focused on outcomes-based contracts and real-world evidence that demonstrate long-term benefit. As a result, organizations that integrate manufacturing innovation, biomarker-driven patient selection, and robust evidence-generation plans are best positioned to capitalize on the current inflection point. Strategic coordination across these domains will determine which therapeutic approaches scale from clinical promise to standard-of-care options for patients.

Analyze the multifaceted operational and strategic consequences of 2025 United States tariff measures on supply chains, manufacturing decisions, and clinical timelines

The imposition of tariffs and trade policy shifts in the United States in 2025 has produced a complex set of downstream effects for the development and delivery of advanced cell therapies, including TIL programs. Supply chains for critical reagents, single-use bioreactors, cold chain packaging, and specialized disposables often span multiple geographies; increases in import duties raise the landed cost of these inputs and can introduce procurement bottlenecks. In turn, sponsors face tighter timelines as sourcing constraints slow manufacturing campaigns and extend clinical trial enrollment windows.

Consequently, companies are recalibrating sourcing strategies to mitigate exposure to tariff-induced cost volatility. Some stakeholders have accelerated qualification of domestic suppliers and diversified vendor lists to include regional manufacturers, while others have evaluated partial reshoring of manufacturing capabilities to reduce reliance on cross-border shipments. These responses can reduce logistical risk but may also necessitate capital investment in new production capacity and workforce training. For smaller developers and academic centers with limited purchasing power, tariff-related cost inflation can disproportionately affect operational budgets and trial feasibility.

Moreover, the policy environment has prompted dialogue between industry and regulators about targeted exemptions for critical medical supplies and streamlined customs processes for clinical materials. Payers and health systems, in turn, are sensitive to any cost increases that could influence reimbursement negotiations and adoption pathways. As mitigation strategies gain traction, stakeholders should prioritize transparency in supplier qualification, contingency planning for reagent shortages, and early engagement with regulators to secure necessary import flexibilities. Ultimately, the ability to manage tariff-related disruptions will influence timelines for commercialization and the equitable distribution of TIL therapies across treatment centers.

Provide a cohesive segmentation-driven perspective that connects clinical indications, cell source choices, end-user settings, distribution pathways, and manufacturing models to strategy

A granular understanding of segmentation is essential to tailor clinical, manufacturing, and commercial strategies for TIL therapy. Based on Indication, studies span breast cancer, lung cancer, and melanoma, each presenting distinct tumor microenvironments, immune infiltration patterns, and historical responsiveness to immunotherapies; these differences shape trial design, biomarker development, and endpoint selection. For instance, melanoma has been an early proving ground for TIL approaches due to its immunogenicity, whereas breast and lung cancer programs often require refined selection criteria and combination regimens to overcome heterogeneous immune landscapes.

Based on Cell Source, the field examines allogeneic and autologous approaches, where autologous therapies leverage patient-specific repertoires and face individualized manufacturing workflows, while investigational allogeneic paradigms aim to streamline logistics through pre-manufactured cell banks, but must address graft-versus-host risks and immunogenicity control. These cell-source considerations directly influence manufacturing architecture, quality-control parameters, and clinical monitoring strategies.

Based on End User, adoption pathways differ across hospitals, research institutes, and specialty clinics; comprehensive cancer centers often serve as early adopters due to integrated capabilities in cell harvesting, lymphodepletion administration, and post-infusion monitoring, whereas regional hospitals may require partnerships or hub-and-spoke models to provide access. Based on Distribution Channel, therapies are distributed via hospital pharmacy, online pharmacy, and retail pharmacy frameworks where applicable, each necessitating distinct cold chain, regulatory compliance, and fulfillment processes. Finally, based on Manufacturing Model, organizations evaluate contract manufacturing organization and in-house manufacturing pathways, weighing trade-offs between speed-to-market, capital expenditure, and quality control. Taken together, these segmentation lenses inform prioritization of investment, site selection for trials, and the design of scalable operational models that align clinical needs with logistical realities.

Examine how regional regulatory frameworks, clinical infrastructure, and payer environments across major geographies influence adoption and access strategies

Regional dynamics play a decisive role in shaping clinical development priorities, regulatory strategy, and access models for TIL therapy. In the Americas, a concentration of leading cancer centers, established cell therapy manufacturing networks, and an active investor base create favorable conditions for early clinical adoption and pilot commercial programs. Regulatory frameworks in this region increasingly balance expedited pathways with stringent quality expectations, which encourages sponsors to generate robust safety and durability data while pursuing accelerated review mechanisms.

Europe, Middle East & Africa presents a heterogeneous landscape where leading academic hubs and national health systems drive innovation in pockets, yet reimbursement policies and regulatory harmonization vary considerably across jurisdictions. Sponsors frequently adopt region-specific evidence strategies and localized manufacturing partnerships to navigate diverse payer requirements and to leverage centers of excellence for clinical trials. Furthermore, collaborative public-private initiatives in certain countries have supported infrastructure investments that strengthen regional capabilities for complex cell therapies.

Asia-Pacific exhibits rapid scaling of clinical trial activity and growing manufacturing capacity, supported by proactive regulatory reforms in several markets and an expanding base of experienced contract manufacturers. Demographic trends and high unmet need in specific cancer indications have accelerated both investigator-led and sponsor-driven studies. However, stakeholders must consider variable intellectual property landscapes, import/export regulations, and differences in hospital readiness when designing market entry and rollout plans. Across regions, the interplay between regulatory policy, payer receptivity, and available clinical infrastructure determines the sequence and pace at which TIL therapies transition from investigational to routine use.

Synthesize the strategic behaviors of innovators, manufacturers, diagnostics providers, and collaborative partners shaping competitive differentiation and operational scale

Company strategies in the TIL therapy domain reveal a mix of research-intensive innovators, specialized manufacturers, diagnostic developers, and strategic collaborators. Innovators emphasize differentiated cell selection methods, potency assays, and clinical programs focused on niche indications or combination regimens, while manufacturing-focused organizations play a critical role in enabling scale through automated expansion systems and closed, single-use platforms. Diagnostic and biomarker firms contribute precision to patient selection and longitudinal monitoring, creating integral links between laboratory capabilities and clinical outcomes.

Strategic partnerships and alliance models are common, with academic medical centers supplying translational expertise and clinical sites, while commercial entities provide capital, regulatory strategy, and manufacturing scale-up. In addition, contract development and manufacturing organizations offer modular services that reduce time-to-clinic for sponsors lacking in-house capacity. Intellectual property positioning around key culture methods, cell processing technologies, and potency markers shapes competitive dynamics and encourages licensing and co-development arrangements.

As the ecosystem matures, companies that adopt integrated strategies-combining robust clinical pipelines with scalable manufacturing and diagnostics-will hold an advantage in navigating regulatory scrutiny and payer engagement. Strategic imperatives include investing in reproducible analytics, forging durable clinical partnerships, and developing commercially viable supply chains that support both centralized and decentralized delivery models.

Recommend targeted operational, clinical, and commercial actions that executives should implement to scale therapy delivery and de-risk commercialization pathways

Industry leaders should adopt a pragmatic, multi-dimensional approach to accelerate development and adoption of TIL therapy while managing operational and financial risk. First, prioritize investments in automated, closed manufacturing systems that reduce variability and accelerate throughput; such investments are essential to move from bespoke processes to reproducible commercial production. Second, diversify the supply base and qualify redundant vendors for critical reagents and disposables to insulate operations from geopolitical and tariff-related disruptions.

Third, integrate biomarker and diagnostic strategies early in clinical development to refine patient selection and to generate compelling evidence for both regulators and payers. Fourth, engage payers proactively to develop outcomes-based reimbursement models and to design real-world evidence collection plans that capture long-term benefit and safety. Fifth, cultivate strategic partnerships with academic centers and experienced contract manufacturers to balance speed-to-clinic with cost-effective scale-up. Sixth, invest in workforce development and training programs for clinical sites to ensure consistent cell collection, handling, and post-infusion care, thereby reducing site-to-site variability.

Finally, adopt an iterative evidence-generation roadmap that sequences pivotal studies, real-world registries, and health economics analyses to support reimbursement and adoption decisions. By aligning technological investment, clinical strategy, and payer engagement, leaders can convert clinical promise into durable patient access while managing the complex operational realities of advanced cell therapies.

Explain a rigorous mixed-methods research framework that integrates expert interviews, regulatory and clinical evidence, operational case studies, and supply chain mapping

The research approach underpinning this analysis combined qualitative and quantitative methodologies to ensure robust triangulation of insights. Primary research included structured interviews with key opinion leaders in oncology, cell therapy manufacturing executives, hospital pharmacy directors, and clinical trial investigators to capture frontline perspectives on operational constraints, clinical design priorities, and adoption drivers. Supplementing primary inputs, a systematic review of peer-reviewed literature, regulatory guidance documents, and clinical trial registries informed the clinical and safety context for TIL programs.

Operationally, the research evaluated manufacturing processes through facility case studies and technical whitepapers describing expansion platforms, closed-system operations, and quality-control frameworks. Supply chain analysis mapped sourcing footprints for critical inputs and assessed logistical vulnerabilities, while scenario-based assessments considered the implications of policy shifts on procurement and distribution. The analysis also incorporated patent landscape reviews and partnership disclosures to understand technology ownership and collaboration trends.

Data validation included cross-referencing interview insights with publicly available regulatory filings, conference presentations, and clinical trial updates, ensuring that findings reflect both practitioner experience and documented evidence. Throughout the research process, emphasis was placed on reproducibility and pragmatic relevance, enabling stakeholders to translate the report's findings into operational and strategic decisions.

Conclude with a concise synthesis emphasizing the scientific promise, operational imperatives, and collaborative actions required to expand patient access and sustain long term impact

Tumor-infiltrating lymphocyte therapy stands at a pivotal moment where scientific maturity intersects with practical imperatives for manufacturing, regulation, and reimbursement. The modality's capacity to elicit durable responses in certain solid tumors positions it as an important complement to existing immunotherapies, provided that developers resolve logistical and evidence-generation challenges. Progress in cell-selection methods, closed manufacturing systems, and combination regimens offers a clear pathway to broader applicability, yet realization of that potential will depend on coordinated investments across the ecosystem.

In conclusion, stakeholders who align clinical development with scalable manufacturing, build resilient supply chains, and engage payers early will be best placed to translate clinical signals into sustainable patient access. Collaborative models that leverage academic expertise, specialized manufacturing partners, and diagnostic integration will accelerate learning cycles and reduce technical risk. Ultimately, a pragmatic focus on reproducible processes, robust biomarkers, and payer-aligned evidence will determine how rapidly TIL therapy moves from specialized centers to a more widely accessible therapeutic option.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tumor-Infiltrating Lymphocyte Therapy Market, by Indication

  • 8.1. Breast Cancer
  • 8.2. Lung Cancer
  • 8.3. Melanoma

9. Tumor-Infiltrating Lymphocyte Therapy Market, by Cell Source

  • 9.1. Allogeneic
  • 9.2. Autologous

10. Tumor-Infiltrating Lymphocyte Therapy Market, by Manufacturing Model

  • 10.1. Contract Manufacturing Organization
  • 10.2. In-House Manufacturing

11. Tumor-Infiltrating Lymphocyte Therapy Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Tumor-Infiltrating Lymphocyte Therapy Market, by Distribution Channel

  • 12.1. Hospital Pharmacy
  • 12.2. Online Pharmacy
  • 12.3. Retail Pharmacy

13. Tumor-Infiltrating Lymphocyte Therapy Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Tumor-Infiltrating Lymphocyte Therapy Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Tumor-Infiltrating Lymphocyte Therapy Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Tumor-Infiltrating Lymphocyte Therapy Market

17. China Tumor-Infiltrating Lymphocyte Therapy Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Achilles Therapeutics
  • 18.6. Adaptimmune Therapeutics plc
  • 18.7. Anocca AB
  • 18.8. Atreca Inc.
  • 18.9. Cellectis S.A.
  • 18.10. Celularity Inc.
  • 18.11. GammaDelta Therapeutics Ltd.
  • 18.12. Immatics N.V.
  • 18.13. Instil Bio Inc.
  • 18.14. Iovance Biotherapeutics Inc.
  • 18.15. Kite Pharma Inc
  • 18.16. Lyell Immunopharma Inc.
  • 18.17. Nykode Therapeutics ASA
  • 18.18. Obsidian Therapeutics Inc.
  • 18.19. PACT Pharma Inc.
  • 18.20. Poseida Therapeutics Inc.
  • 18.21. Precigen Inc.
  • 18.22. RheinCell Therapeutics GmbH
  • 18.23. SQZ Biotechnologies Company
  • 18.24. Tessa Therapeutics Ltd.
  • 18.25. TILT Biotherapeutics
  • 18.26. TScan Therapeutics Inc.
  • 18.27. Turnstone Biologics Corp.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MELANOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MELANOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CONTRACT MANUFACTURING ORGANIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY IN-HOUSE MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 105. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 106. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. GCC TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 122. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 123. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 124. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. G7 TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 129. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 130. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. NATO TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY MANUFACTURING MODEL, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA TUMOR-INFILTRATING LYMPHOCYTE THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)